Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Free Cash Flow (2016 - 2025)

Cytokinetics (CYTK) has disclosed Free Cash Flow for 16 consecutive years, with -$204.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow changed N/A to -$204.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$341.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$534.8 million for FY2025, 33.77% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$204.0 million at Cytokinetics, down from -$137.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$25.6 million in Q4 2021, with the low at -$204.0 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$90.7 million, with a median of -$94.5 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 472.6% in 2021, then grew 23.22% in 2022.
  • Over 5 years, Free Cash Flow stood at -$25.6 million in 2021, then plummeted by 254.21% to -$90.7 million in 2022, then increased by 18.27% to -$74.1 million in 2023, then crashed by 37.48% to -$101.9 million in 2024, then tumbled by 100.24% to -$204.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$204.0 million, -$137.3 million, and -$101.9 million for Q4 2025, Q1 2025, and Q3 2024 respectively.